But the whole point of the biotech industry is to blur those boundaries, and Myriad did.
But until yesterday I would have said the same thing about the chances of patent reform in biotech, too.
The ruling will have profound effects on medical research, genetic science, and the biotech industry.
This has big implications for how biotech research will fare in the future.
NIH has a small RD budget relative to private companies in the drug and biotech industries.
